PerkinElmer announces Street-beating Q2, plans to acquire BioLegend for $5.3B

By Sean Whooley | July 26, 2021

PerkinElmer (NYSE:PKI) today posted Street-beating second-quarter revenues and announced the $5.3 billion acquisition of BioLegend.

The Waltham, Mass.-based company posted profits of $245.9 million, or $2.19 per share, on sales of $1.2 billion for the three months ended July 4, 2021, for a 79.3% bottom-line gain on sales growth of 51.3%.

Get the full story at our sister site, MassDevice.

Filed Under: Drug Delivery, Drug Discovery, Drug Discovery and Development
Tagged With: BioLegend, PerkinElmer

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].